Your browser doesn't support javascript.
loading
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.
Dingemans, Anne-Marie C; Hendriks, Lizza E L; Berghmans, Thierry; Levy, Antonin; Hasan, Baktiar; Faivre-Finn, Corinne; Giaj-Levra, Matteo; Giaj-Levra, Niccolò; Girard, Nicolas; Greillier, Laurent; Lantuéjoul, Sylvie; Edwards, John; O'Brien, Mary; Reck, Martin; Smit, Egbert F; Van Schil, Paul; Postmus, Pieter E; Ramella, Sara; Lievens, Yolande; Gaga, Mina; Peled, Nir; Scagliotti, Giorgio V; Senan, Suresh; Paz-Ares, Luiz; Guckenberger, Matthias; McDonald, Fiona; Ekman, Simon; Cufer, Tanja; Gietema, Hester; Infante, Maurizio; Dziadziuszko, Rafal; Peters, Solange; Porta, Ramon Rami; Vansteenkiste, Johan; Dooms, Christophe; de Ruysscher, Dirk; Besse, Benjamin; Novello, Silvia.
Afiliação
  • Dingemans AC; Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Pulmonary Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands. Electronic address
  • Hendriks LEL; Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands.
  • Berghmans T; Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Brussels, Belgium; Jules Bordet Institute, Brussels Free University, Brussels, Belgium.
  • Levy A; Department of Radiation Oncology, Gustave Roussy, Thoracic Oncology Institute (IOT), Villejuif, France; Paris Saclay University, Saint-Aubin, France.
  • Hasan B; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Faivre-Finn C; The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom.
  • Giaj-Levra M; Respiratory Oncology Unit, Department of Thoracic and Vascular disease, Grenoble Alpes University Hospital, Grenoble, France.
  • Giaj-Levra N; Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy; Department of Oncology, University of Turin, Torino, Italy.
  • Girard N; Department of Medical Oncology, Institute Curie, Thorax Institute Curie Montsouris, Paris, France.
  • Greillier L; Multidisciplinary Oncology and Therapeutic Innovations, Marseille University Hospital (APHM), Marseille, France; Aix Marseille University, Marseille, France.
  • Lantuéjoul S; Department of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France; Université Grenoble Alpes, INSERM U1209/CNRS 5309 Institute for Advanced Biosciences, Grenoble France.
  • Edwards J; Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, United Kingdom.
  • O'Brien M; Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom.
  • Reck M; Department of Thoracic Oncology, Airway Research Center North, German Center of Lung Diseases, Lung Clinic, Grosshansdorf, Germany.
  • Smit EF; dept of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Van Schil P; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, B-2650 Edegem (Antwerp), Belgium.
  • Postmus PE; Department of pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
  • Ramella S; Radiation Oncology, Campus Bio-Medico University, Rome, Italy.
  • Lievens Y; Radiation Oncology Department, Ghent University Hospital Ghent, Belgium; Ghent University, Ghent, Belgium.
  • Gaga M; Seventh Respiratory Medicine Dept, Athens Chest Hospital Sotiria, Athens, Greece; European Respiratory Society, Lausanne, Switzerland.
  • Peled N; The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Cancer Center, Beer-Sheva, Israel; Ben Gurion University, Beer-Sheva, Israel.
  • Scagliotti GV; Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.
  • Senan S; Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, The Netherlands.
  • Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Guckenberger M; Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
  • McDonald F; Department of Radiotherapy, Royal Marsden Hospital, London, United Kingdom.
  • Ekman S; Thoracic Oncology Center, Karolinska University Hospital/ Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Cufer T; University Clinic Golnik, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Slovenia.
  • Gietema H; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Infante M; Thoracic Surgery Dept. University and Hospital Trust - Ospedale Borgo Trento, Verona, Italy.
  • Dziadziuszko R; Department of Oncology and Radiotherapy, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Peters S; Oncology Department, University Hospital (CHUV), 1011 Lausanne, Switzerland.
  • Porta RR; Department of Thoracic Surgery, Mútua Terrassa University Hospital, University of Barcelona, Terrassa, Terrassa, Barcelona, Spain; Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain.
  • Vansteenkiste J; Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium.
  • Dooms C; Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium.
  • de Ruysscher D; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands.
  • Besse B; Paris Saclay University, Saint-Aubin, France; Department of cancer medicine, Gustave Roussy, Villejuif, France.
  • Novello S; Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.
J Thorac Oncol ; 14(12): 2109-2119, 2019 12.
Article em En | MEDLINE | ID: mdl-31398540
INTRODUCTION: Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. METHODS: A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. RESULTS: It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. CONCLUSION: A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Guideline Limite: Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Guideline Limite: Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article